利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

703 条记录 (耗时 0.03 秒)

    COMPOSITION BASED ON A STABILIZED SOLUTION OF ACTIVE INGREDIENTS
    13.
    发明申请
    COMPOSITION BASED ON A STABILIZED SOLUTION OF ACTIVE INGREDIENTS 审中-公开
    基于稳定的有效成分溶液的组成

    公开(公告)号：WO2015183230A1

    公开(公告)日：2015-12-03

    申请号：PCT/UA2015000047

    申请日：2015-06-02

    申请人： DERKACH NATALIIA MYKOLAIVNA

    发明人： DERKACH NATALIIA MYKOLAIVNA

    IPC分类号： A61K9/08 ,  A61K31/14 ,  A61K31/728 ,  A61K47/02

    CPC分类号： A61K9/08 ,  A61K9/0014 ,  A61K9/0034 ,  A61K31/14 ,  A61K31/223 ,  A61K31/728 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K2300/00

    摘要： This invention relates to pharmaceutical compositions (variants) based on a stabilized solution of two active ingredients, said stabilized solution of two active ingredients comprising, as first active ingredient, low-molecular weight hyaluronic acid and/or a pharmaceutically acceptable salt thereof, wherein the molecular mass of said acid or salt is from 100 kDa to 400 kDa or, in a variant, from 400 kDa to 2.5 MDa, and, as second active ingredient, Decametoxin or a water-soluble salt thereof, and a stabilizer in the form of a pharmaceutically acceptable salt that is capable of dissolving in water and dissociating in aqueous solutions into metal cations and acid residue anions, or a mixture of such salts, wherein the stabilizer is capable of forming water-soluble compounds with hyaluronic acid and/or a pharmaceutically acceptable salt thereof and Decametoxin or a water-soluble salt thereof, simultaneously. The stabilized solution further contains at least one pharmaceutically acceptable additive.

    摘要翻译： 本发明涉及基于两种活性成分的稳定化溶液的药物组合物（变体），所述两种活性成分的稳定化溶液包含作为第一活性成分的低分子量透明质酸和/或其药学上可接受的盐，其中所述 所述酸或盐的分子量为100kDa至400kDa或在一个变体中为400kDa至2.5MDa，并且作为第二活性成分，十甲基毒素或其水溶性盐和稳定剂形式为 能够溶解于水中并且在水溶液中离解成金属阳离子和酸残基阴离子的药学上可接受的盐，或者这些盐的混合物，其中所述稳定剂能够与透明质酸和/或其药学上可接受的盐形成水溶性化合物 同时可接受的盐和十倍体毒素或其水溶性盐。 稳定化溶液还含有至少一种药学上可接受的添加剂。

    METHOD FOR ASSESSING AND TREATING OR PREVENTING IMPAIRED PLASMA POLAR LIPID LEVELS
    15.
    发明申请
    METHOD FOR ASSESSING AND TREATING OR PREVENTING IMPAIRED PLASMA POLAR LIPID LEVELS 审中-公开
    评估和处理或预防等离子体极性脂质水平的方法

    公开(公告)号：WO2015160247A1

    公开(公告)日：2015-10-22

    申请号：PCT/NL2015/050244

    申请日：2015-04-14

    申请人： N.V. NUTRICIA

    发明人： VAN WIJK, Nick

    IPC分类号： A61K31/095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7072 ,  A61K31/714 ,  A61P25/28 ,  A61K31/685

    CPC分类号： A61K31/714 ,  A61K31/095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

    摘要翻译： 本发明涉及用于制备用于预防或治疗一种或多种极性脂质受损血浆水平的组合物的制剂的用途，所述极性脂质如磷脂酰胆碱[PC]选自磷脂酰胆碱二酰基C36：6 [PCaa C36： 6]，磷脂酰胆碱二酰基C38：0 [PCaa C38：0]，磷脂酰胆碱二酰基C38：6 [PC aa C38：6]，磷脂酰胆碱二酰基C40：6 [PCaa C40：6]和磷脂酰胆碱酰基 - 烷基C40： PC ae C40：6]在临床前AD或MCI受试者或具有高发展AD或MCI可能性的受试者中，并且其中所述受试者被给予包含至少一种，优选至少两种，最优选全部B族维生素 选自维生素B6，维生素B12和维生素B9组成。

    COMBINATION THERAPY COMPRISING AN OMEGA-3 FATTY ACID, A FOLATE SPECIES AND A VITAMIN B12 SPECIES
    16.
    发明申请
    COMBINATION THERAPY COMPRISING AN OMEGA-3 FATTY ACID, A FOLATE SPECIES AND A VITAMIN B12 SPECIES 审中-公开
    包含欧米伽-3脂肪酸，假体物种和维生素B12物种的组合治疗

    公开(公告)号：WO2015140545A1

    公开(公告)日：2015-09-24

    申请号：PCT/GB2015/050786

    申请日：2015-03-17

    申请人： ISIS INNOVATION LIMITED

    发明人： SMITH, David ,  JERNEREN, Fredrik ,  REFSUM, Helga

    IPC分类号： A61K31/202 ,  A61K31/519 ,  A61K31/714 ,  A61P25/28

    CPC分类号： A61K31/202 ,  A61K9/0053 ,  A61K31/14 ,  A61K31/205 ,  A61K31/232 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/714 ,  A61P25/28 ,  A61K2300/00

    摘要： The present invention provides a combined therapy comprising the use of one or more omega -3 fatty acids and one or more B vitamins and for treating cognitive impairment, such cognitive impairment disorders include, especially but not exclusively, Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD). The present invention also provides a treatment for individuals suffering from cognitive impairment disorders that occur as a result of brain or cerebral atrophy,the invention includes inter alia methods of treating and/or reducing progression of brain atrophy and pharmaceutical compositions and nutritional supplements therefor.

    摘要翻译： 本发明提供了包括使用一种或多种ω-3脂肪酸和一种或多种B族维生素并用于治疗认知障碍的组合疗法，所述认知障碍障碍包括，特别地但不排他地包括轻度认知障碍（MCI）和阿尔茨海默病 疾病（AD）。 本发明还提供了治疗由于脑或脑萎缩而发生的认知障碍障碍的个体，本发明尤其包括治疗和/或减少脑萎缩进程的方法以及药物组合物和营养补充剂。

    COMPOSITIONS CONTAINING PUFA, URIDINE AND CHOLINE AND METHODS OF USE THEREOF
    17.
    发明申请
    COMPOSITIONS CONTAINING PUFA, URIDINE AND CHOLINE AND METHODS OF USE THEREOF 审中-公开
    含有PUFA，URIDINE和COLINE的组合物及其使用方法

    公开(公告)号：WO2015138879A1

    公开(公告)日：2015-09-17

    申请号：PCT/US2015/020420

    申请日：2015-03-13

    申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY

    发明人： WURTMAN, Richard

    IPC分类号： A61K31/506

    CPC分类号： A61K31/7072 ,  A61K31/14 ,  A61K31/201 ,  A61K31/202 ,  A61K31/685 ,  G01N33/92 ,  G01N2405/04 ,  G01N2800/52 ,  A61K2300/00

    摘要： The invention is directed to a method for increasing phosphatidylcholine in the blood of a subject comprising administering to the subject a composition having uridine or a metabolic precursor of uridine; choline or a metabolic precursor of choline; and at least one omega-3 fatty acid and/or omega-6 fatty acid, the phosphatidylcholine has a glycerol portion and the glycerol portion is bonded to two fatty acids and the total amount of carbons in the fatty acids is about 16 to 40 carbon atoms.

    摘要翻译： 本发明涉及一种增加受试者血液中磷脂酰胆碱的方法，包括向受试者施用具有尿苷或尿苷代谢前体的组合物; 胆碱或胆碱代谢前体; 和至少一种ω-3脂肪酸和/或ω-6脂肪酸，所述磷脂酰胆碱具有甘油部分，并且所述甘油部分与两种脂肪酸结合，并且所述脂肪酸中的碳的总量为约16至40碳 原子。